Interview with Ali Akyildiz, General Manager, IMS Health Turkey
Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS…
IMS started to operate in Turkey through some other local companies in the late 60s. The first report was published in 1968. Since the inception of the local entity in 1990, it has grown significantly serving both local and multinational clients by providing information, technology solutions and professional services including consulting. Our information panel covers over 99% of the market in terms of pharmaceutical sales data and accepted as a gold standard in the industry. Our consulting team consists of 20 professional consultants and acting as a hub for Middle East to support our clients in solving their problems in portfolio strategy, market entry, mergers & acquisitions and commercial effectiveness.
Currently, IMS Turkey is serving more than 150 clients in these areas with about 140 professionals with our recent Cegedim acquisition.
Contact Details
Gazeteciler Mahallesi
Yazarlar Sokak – No. 8, 34394 Esentepe – Sisli
Istanbul
Turkey
Tel: +90 212 355 57 00
Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS…
PharmaBoardroom talked to Sr. Managing Director of Medtronic Turkey, Ayhan Ozturk about improving patient outcomes, how the company introduced a whole new standard on integrated healthcare, and their recent USD $25 million…
Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also…
Sevi Firat, Founding Partner of Firat Izgi discusses the legal challenges facing pharmaceutical companies looking to penetrate the healthcare market in Turkey, the evolution of the legal landscape and her…
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
A founding partner of YükselKarkınKüçük, Gökhan Gökçe discusses the firm’s involvement with several high profile cases concerning the healthcare and life science sector’s reference pricing system, and also elaborates on…
The managing director of DHL Express Turkey, Markus Reckling highlights the strategic importance of Turkey to the global DHL Express portfolio and elaborates on the market opportunities present for DHL’s…
The co-founder of Ekin Kimya discusses the need for greater regulation and monitoring of raw materials used in Turkish pharmaceutical manufacturing, his company’s key role as an educator and advisor…
Novartis country president Peter Catalino discusses the need for Turkey to introduce financial investment incentives to compete more effectively with other countries for investments in R&D and manufacturing. You arrived…
The chairman and CEO of Santa Farma discusses how the Turkish pharmaceutical landscape has evolved in response to the government’s healthcare transformation programs. He also enumerates various strategic initiatives the…
Omega CRO has evolved from its beginnings as a CRO contracted by local and multinational pharmaceutical companies into an organization leading clinical, epidemiological and observational studies of public interest across…
The president of the Turkish Drug and Medical Device Agency (TITCK) discusses new initiatives and reforms being carried out by his agency, including its work towards becoming a PIC/s member, and…
The CEO of Centurion shares his ambitious vision for the company’s expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing sales in more than…
See our Cookie Privacy Policy Here
